{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:37:31Z","timestamp":1793108251629,"version":"4.5.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to explore the shared mechanism and candidate drugs of multiple sclerosis (MS) and Sj\u00f6gren\u2019s syndrome (SS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MS- and SS-related susceptibility genes and differentially expressed genes (DEGs) were identified by bioinformatics analysis based on genome-wide association studies (GWAS) and transcriptome data from GWAS catalog and Gene Expression Omnibus (GEO) database. Pathway enrichment, Gene Ontology (GO) analysis, and protein\u2013protein interaction analysis for susceptibility genes and DEGs were performed. The drugs targeting common pathways\/genes were obtained through Comparative Toxicogenomics Database (CTD), DrugBank database, and Drug\u2013Gene Interaction (DGI) Database. The target genes of approved\/investigational drugs for MS and SS were obtained through DrugBank and compared with the common susceptibility genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on GWAS data, we found 14 hub common susceptibility genes (<jats:italic>HLA-DRB1<\/jats:italic>, <jats:italic>HLA-DRA<\/jats:italic>, <jats:italic>STAT3<\/jats:italic>, <jats:italic>JAK1<\/jats:italic>, <jats:italic>HLA-B<\/jats:italic>, <jats:italic>HLA-DQA1<\/jats:italic>, <jats:italic>HLA-DQA2<\/jats:italic>, <jats:italic>HLA-DQB1<\/jats:italic>, <jats:italic>HLA-DRB5<\/jats:italic>, <jats:italic>HLA-DPA1<\/jats:italic>, <jats:italic>HLA-DPB1<\/jats:italic>, <jats:italic>TYK2<\/jats:italic>, <jats:italic>IL2RA<\/jats:italic>, and <jats:italic>MAPK1<\/jats:italic>), with 8 drugs targeting two or more than two genes, and 28 common susceptibility pathways, with 15 drugs targeting three or more than three pathways. Based on transcriptome data, we found 3 hub common DEGs (<jats:italic>STAT1<\/jats:italic>, <jats:italic>GATA3<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic>) with 3 drugs and 10 common risk pathways with 435 drugs. \u201cJAK-STAT signaling pathway\u201d was included in common susceptibility pathways and common risk pathways at the same time. There were 133 overlaps including JAK-STAT inhibitors between agents from GWAS and transcriptome data. Besides, we found that <jats:italic>IL2RA<\/jats:italic> and <jats:italic>HLA-DRB1<\/jats:italic>, identified as hub common susceptibility genes, were the targets of daclizumab and glatiramer that were used for MS, indicating that daclizumab and glatiramer may be therapeutic for SS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We observed the shared mechanism of MS and SS, in which JAK-STAT signaling pathway played a vital role, which may be the genetic and molecular bases of comorbidity of MS with SS. Moreover, JAK-STAT inhibitors were potential therapies for MS and SS, especially for their comorbidity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.857014","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T05:08:58Z","timestamp":1646802538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["The Shared Mechanism and Candidate Drugs of Multiple Sclerosis and Sj\u00f6gren\u2019s Syndrome Analyzed by Bioinformatics Based on GWAS and Transcriptome Data"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiangxiang","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Rang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple Sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.013","article-title":"Sjogren's Syndrome and Multiple Sclerosis: Two Sides of the Same Coin? [Journal Article; Review]","volume":"15","author":"Masi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sjogren's Syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104728","article-title":"Sjogren's Syndrome","volume":"9","author":"Mavragani","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1120","article-title":"The NHGRI-EBI GWAS Catalog of Published Genome-Wide Association Studies, Targeted Arrays and Summary Statistics 2019","volume":"47","author":"Buniello","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/pro.4172","article-title":"KEGG Mapping Tools for Uncovering Hidden Features in Biological Data","volume":"31","author":"Kanehisa","year":"2022","journal-title":"Protein Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"Clusterprofiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (N Y)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"A. Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"A. Bioinformatics Enrichment Tools: Paths Toward the Comprehensive Functional Analysis of Large Gene Lists","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1131","article-title":"STRING V11: Protein-Protein Association Networks With Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: Archive for Functional Genomics Data Sets\u2013Update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa891","article-title":"Comparative Toxicogenomics Database (CTD): Update 2021","volume":"49","author":"Davis","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A Major Update to the DrugBank Database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1084","article-title":"Integration of the Drug-Gene Interaction Database (DGIdb 4.0) With Open Crowdsource Efforts","volume":"49","author":"Freshour","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jamia.2000.0070313","article-title":"Design and Implementation of a National Clinical Trials Registry","volume":"7","author":"McCray","year":"2000","journal-title":"J Am Med Inform Assoc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"a029025","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T Cells in Multiple Sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08793-7","article-title":"Immunobiology of T Cells in Sjogren's Syndrome","volume":"60","author":"Yao","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.13885\/j.issn.1000-2812.2020.06.008","article-title":"Advances in the Study of T-Cell Subsets in the Pathogenesis of Primary Sj\u00f6gren's Syndrome","volume":"46","author":"Wang","year":"2020","journal-title":"J Lanzhou Univ (Medical Sciences)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions Between Genetic, Lifestyle and Environmental Risk Factors for Multiple Sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13032","article-title":"Environmental Factors in the Pathogenesis of Primary Sjogren's Syndrome","volume":"287","author":"Bjork","year":"2020","journal-title":"J Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr Virus and Systemic Autoimmune Diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12954","article-title":"The Identification of Up-Regulated ebv-miR-BHRF1-2-5p Targeting MALT1 and ebv-miR-BHRF1-3 in the Circulation of Patients With Multiple Sclerosis","volume":"189","author":"Wang","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT Signaling Pathway in Regulation of Innate Immunity in Neuroinflammatory Diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818347116","article-title":"MAPK Pathway and B Cells Overactivation in Multiple Sclerosis Revealed by Phosphoproteomics and Genomic Analysis","volume":"116","author":"Kotelnikova","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-180352","article-title":"Analysis of STAT1, STAT2 and STAT3 mRNA Expression Levels in the Blood of Patients With Multiple Sclerosis","volume":"27","author":"Manoochehrabadi","year":"2019","journal-title":"Hum Antibodies"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0012","article-title":"Involvement of the Janus Kinase\/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis","volume":"34","author":"Benveniste","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1913997117","article-title":"STAT3 Signaling in Myeloid Cells Promotes Pathogenic Myelin-Specific T Cell Differentiation and Autoimmune Demyelination","volume":"117","author":"Lu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/pharmaceutics13070925","article-title":"Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing-Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL\/J Mice","volume":"13","author":"Alhazzani","year":"2021","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa695","article-title":"Increased Expression of Interleukin-21-Inducible Genes in Minor Salivary Glands Are Associated With Primary Sjogren's Syndrome Disease Characteristics","volume":"60","author":"Chen","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.1038\/s41598-021-90569-w","article-title":"Gene Expression Alterations in Salivary Gland Epithelia of Sjogren's Syndrome Patients Are Associated With Clinical and Histopathological Manifestations","volume":"11","author":"Dela","year":"2021","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib Counteracts IL-6 Overexpression Induced by Deficient Autophagy: Implications in Sjogren's Syndrome","volume":"60","author":"Barrera","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2395","article-title":"The Genetics of Multiple Sclerosis: SNPs to Pathways to Pathogenesis","volume":"9","author":"Oksenberg","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.8.1511","article-title":"Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed With a Peptide From Human Myelin Basic Protein","volume":"188","author":"Smith","year":"1998","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.002","article-title":"HLA and Sjogren's Syndrome Susceptibility. A Meta-Analysis of Worldwide Studies","volume":"11","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2792","article-title":"L.Variants at Multiple Loci Implicated in Both Innate and Adaptive Immune Responses are Associated With Sjogren's Syndrome","volume":"45","author":"Lessard","year":"2013","journal-title":"Nat Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2779","article-title":"A Genome-Wide Association Study in Han Chinese Identifies a Susceptibility Locus for Primary Sjogren's Syndrome at 7q11.23","volume":"45","author":"Li","year":"2013","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647588","article-title":"Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study","volume":"12","author":"Lu","year":"2021","journal-title":"Front Immunol"},{"key":"B41","article-title":"Evaluation of Soluble CD25 as a Clinical and Autoimmune Biomarker in Primary Sjogren's Syndrome","author":"Chen","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23606","article-title":"Inhibition of MAPK\/ERK Pathway Promotes Oligodendrocytes Generation and Recovery Of Demyelinating Diseases","volume":"67","author":"Suo","year":"2019","journal-title":"Glia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12765","article-title":"Upregulation of IL-6 Expression in Human Salivary Gland Cell Line by IL-17 via Activation of P38 MAPK, ERK, PI3K\/Akt, and NF-kappaB Pathways","volume":"47","author":"Wei","year":"2018","journal-title":"J Oral Pathol Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2021-0296","article-title":"Construction of a lncRNA-miRNA-mRNA Network to Determine the Key Regulators of the Th1\/Th2 Imbalance in Multiple Sclerosis","volume":"13","author":"Azari","year":"2021","journal-title":"Epigenomics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15021700","article-title":"Regulation of an Autoimmune Model for Multiple Sclerosis in Th2-Biased GATA3 Transgenic Mice","volume":"15","author":"Fernando","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00085","article-title":"M. Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase Gamma (PI3Kgamma) Inhibitors With Potential for the Treatment of Multiple Sclerosis (Ms)","volume":"61","author":"Come","year":"2018","journal-title":"J Med Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107904","article-title":"The PI3Kdelta Inhibitor Parsaclisib Ameliorates Pathology and Reduces Autoantibody Formation in Preclinical Models of Systemic Lupus Erythematosus and Sjgren's Syndrome","volume":"98","author":"Scuron","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and Safety Profiles of JAK\/STAT Signaling Inhibitors. Are These Small Molecules Also Smart","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.650708","article-title":"Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase\/Signal Transducer and Activator of Transcription Signaling Pathway","volume":"12","author":"Dang","year":"2021","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119395","article-title":"Ruxolitinib Attenuates Experimental Autoimmune Encephalomyelitis (EAE) Development as Animal Models of Multiple Sclerosis (MS)","volume":"276","author":"Hosseini","year":"2021","journal-title":"Life Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4049\/jimmunol.1301513","article-title":"Therapeutic Efficacy of Suppressing the Jak\/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis","volume":"192","author":"Liu","year":"2014","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1986063","article-title":"Tofacitinib Enhances Remyelination and Improves Myelin Integrity in Cuprizone-Induced Mice","volume":"43","author":"Gunaydin","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/art.40589","article-title":"JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjogren's Syndrome. [Journal Article; Research Support, Non-U.S. Gov't]","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS Demyelination During Tofacitinib Therapy: First Report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.857014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T05:09:03Z","timestamp":1646802543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.857014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2022.857014"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.857014","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"857014"}}